Effect of 180 mgTicagrelor Compared With 90 mg Ticagrelor on Platelet Reactivity in Patients Undergoing Elective PCI.
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 74
- 试验地点
- 1
- 主要终点
- Platelet reactivity
研究概览
简要总结
Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes. Compared with clopidogrel, Ticagrelor is more powerful antiplatelet drug. However, because of increased bleeding and dyspnea risk, both loading double dose and following second dose time had potential risk and inconvenient in routine clinical work, especially in elective PCI of comparable stable patients in Chinese. The benefit and risk should be balanced in such patients. The investigators supposed loading single dose and followed by second routine time dose was superior to clopidogrel and safer than ticagrelor previously prescribed.
详细描述
All admission patients were divided into two groups, the first group were prescribed loading dose (180 mg) ticagrelor, the second group were prescribed with 90 mg ticagrelor. We measured both platelet activity and platelet reactivity using the LTA at baseline, pre-operation and post-operation. All bleeding or dyspnea events were recorded in hospital period.
Primary endpoints: platelet activity, platelet reactivity using the LTA and safety events were recorded in hospital period.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •coronary artery disease, percutaneous coronary intervention
排除标准
- •high risk bleeding patient, allergic to the drugs
结局指标
主要结局
Platelet reactivity
时间窗: 1 year
LTA and TEG used to measure the effect of Platelet reactivity
次要结局
未报告次要终点
研究者
quan li
associate chief physician
Beijing Anzhen Hospital